Sun Pharmaceutical , India's top drugmaker by market capitalisation, reported a better-than-expected 91% rise in December quarter net profit on robust sales by Israeli unit Taro Pharmaceutical Industries .
Sales in the US also helped, said the company, which makes generic drugs and provides contract research and manufacturing services.
Sun Pharma's consolidated net profit rose to Rs 668 crore in the third quarter ended December 31, from Rs 35 crore a year ago.
Analysts estimated the net profit at Rs 527 crore, according to Thomson Reuters StarMine data.
Sales rose 37.3% to Rs 2,145 crore, it said.
Taro, in which Sun Pharma owns about 67% and has made an offer to acquire the company fully, reported a net income of Rs 308 crore on a net sales of Rs 7.32 crore in the quarter.
"Business performance is in line with our expectations," Chairman Dilip Shanghvi said in a statement. "We expect the momentum to continue."
The company, however, warned the strong sales and profit growth of Taro might not be sustainable as it was driven by increased selling prices for select products in the US.
Valued at USD 11.34 billion, shares in Sun Pharma closed up were up 2.2% at Rs 553.15 on Monday when the Mumbai market rose 0.14%.
US SALES SURGE
Sun Pharma, which draws more than half of its revenue from the United States, also benefited from a sharp depreciation in the value of the rupee.
Its U.S. formulations sales rose 47 percent to 10.28 billion rupees in the quarter, when the Indian rupee fell more than 7 percent versus the U.S. dollar.
Its Indian rival Dr Reddy's Laboratories Ltd also reported more-than-double sales in North America over the same period while Lupin's business grew 32.4%.
Indian drugmakers, which account for about a third of U.S. applications for approval to sell generics, are expected to add$2 billion to $2.5 billion in US sales in the next five years, doubling their revenue the country.
Drugs worth more than USD 140 billion are likely to go off patent in the next five years.
In the next few years, Sun Pharma, along with Ranbaxy Laboratories , Dr Reddy's Laboratories and Lupin will compete for a host of big-ticket drugs losing patent protection.
These include Forest's Alzheimer's drug Namenda, anti-depressant Lexapro, and the blood clot drug Plavix, sold jointly by Bristol-Myers Squibb Co and Sanofi .
Sun Pharma's Indian formulations business grew 17% to Rs 695 crore compared with an 11% rise for Dr Reddy's and 29.3% for Lupin.
"Although the last two quarters were kind of an aberration, Taro will continue to be the growth driver for the company," said Siddhant Khandekar, analyst at ICICI Direct in Mumbai.
The Mumbai-based drugmaker's operating margin was at a healthy 40 percent.
"Considering the profitability, the stock will remain at a high valuation trajectory in the future."
Source: www.moneycontrol.com
Thanks,
Gaurav Agarwal
Head Dealer
DENIP Consultants Pvt Ltd
No comments:
Post a Comment